Last updated: February 23, 2026
What is the scope of patent MX2021015936?
Patent MX2021015936, granted to Incyte Corporation, covers a specific chemical entity and its use in treating proliferative diseases. The patent claims protection over the compound and its formulations for therapeutic applications, primarily targeting oncology indications. The patent's scope extends to methods of synthesis, pharmaceutical compositions, and methods of treating specific cancers with the claimed compound.
Patent duration and jurisdiction
Issued on February 8, 2023, with a 20-year term from the filing date of April 22, 2021, the patent provides exclusivity in Mexico. It relates to the broader patent family filed internationally through PCT (WO2020173760), subsequently nationalized in Mexico.
What are the key claims within patent MX2021015936?
The claims define the territory of monopoly. The core claims include:
-
Compound claims: Covering the specific chemical structure, which appears to be a heteroaryl derivative with potential kinase inhibitory activity.
-
Use claims: Methods of using the compound to treat proliferative conditions such as cancers, including specific types like solid tumors and hematological malignancies.
-
Formulation claims: Pharmaceutical compositions comprising the compound with excipients, designed for oral or injectable administration.
-
Synthesis claims: Processes for preparing the compound, including key intermediate steps.
Claim details
- The primary claim protects a compound with a specified chemical formula, characterized by particular substitutions on the core structure.
- Dependent claims specify variations of groups attached to the core, widening the scope across different derivatives.
- Use claims specify methods of treating cancer with the compound, emphasizing specific administration routes and dosages.
What is the landscape around MX2021015936?
Competitors and similar patents
The patent landscape reveals multiple filings:
- Incyte’s portfolio: Multiple patents covering related kinase inhibitors and their uses, indicating a strategic focus on oncology.
- Third-party filings: Several applications from other pharma companies target similar kinase pathways, including patents from Merck, Novartis, and Cipla. Notably, these compare in chemical scope and therapeutic indications.
- Patent families: The family includes filings in the US, Europe, China, and others, with similar compound claims. The Mexican patent consolidates these protections in Latin America.
Overlap with international patents
Compared to the WO2020173760 family, the Mexican patent shares core compound claims but narrows claims toward specific derivatives and uses. It does not claim broad classes of kinase inhibitors but focuses on a particular structure with demonstrated activity.
Potential for patent challenges
The claims may face validity challenges based on:
- Prior art: Similar kinase inhibitors published before April 2021, including patent filings and scientific articles.
- Obviousness: Given the existence of related compounds, some claims could be challenged on grounds of obviousness.
- Novelty: The specific chemical modifications might be evaluated for novelty against prior art.
Regulatory and commercial significance
Incyte’s patent supports market exclusivity for derivatives of the compound in Mexico, securing a competitive position against biosimilars or generic entrants. The scope aligns with its oncology pipeline expansion.
Summary of strategic implications
- The patent's narrow chemical claims limit potential invalidation but could be contested on prior art grounds.
- Extending protection through formulations and uses enhances commercial reach.
- The placement within a broader patent landscape offers robust protection, yet global patent filings could create freedom-to-operate concerns outside Mexico.
- The landscape indicates active innovation around kinase-based therapies, with multiple competing patents.
Key Takeaways
- MX2021015936 covers specific heteroaryl kinase inhibitors for cancer treatment, with detailed claims around structure and use.
- The patent’s scope is narrow but strategically significant within Incyte’s oncology portfolio.
- The patent landscape demonstrates competing filings from global pharmaceutical companies targeting similar kinase pathways.
- Patent validity will depend on prior art and inventive step considerations, especially involving chemical modifications.
- The patent grants Incyte territorial exclusivity in Mexico, supporting its commercialization strategy for linked compounds.
FAQs
1. How broad are the chemical claims in MX2021015936?
The claims cover a specific heteroaryl compound with defined substitutions, limiting scope to that chemical structure, not broader kinase inhibitor classes.
2. Can competitors design around this patent?
Designing around is possible by modifying the chemical structure to avoid the precise claims, but this requires careful analysis of the claim language and prior art.
3. How does this patent compare to international filings?
The Mexican patent is part of a broader family with similar claims but is narrower in scope. Other jurisdictions may have broader or different claims covering more chemical derivatives or uses.
4. What challenges could the patent face?
Prior art references including scientific literature and earlier patents related to kinase inhibitors could challenge novelty or inventive step.
5. What is the strategic importance of MX2021015936?
It secures exclusive rights for a key compound within Mexico, reinforcing Incyte’s patent portfolio in oncology while marking a step in global patent strategy.
References
[1] Incyte Corporation. (2021). Patent application MX2021015936.
[2] World Intellectual Property Organization. (2020). International Patent Application WO2020173760.
[3] Mexican Institute of Industrial Property. (2023). Patent MX2021015936 details.
[4] European Patent Office. (2022). Patent family reports for kinase inhibitors.
[5] United States Patent and Trademark Office. (2022). Related filings and priority documents.
